{"brief_title": "PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.", "brief_summary": "This 2-arm study was designed to evaluate the efficacy, safety, and tolerability of prophylactic PEGASYS plus COPEGUS after liver transplantation for hepatitis C, compared to initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection. The anticipated time on study treatment was 3-12 months, and the target sample size was 100-500 individuals.", "condition": "Hepatitis C, Chronic", "intervention_type": "Drug", "intervention_name": "Copegus", "description": "400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks", "arm_group_label": "1", "criteria": "Inclusion Criteria: - Adult patients at least 18 years of age - Positive hepatitis C virus RNA at pre-transplantation - Primary, single-organ recipient (cadaveric donor) - Liver transplant between 10 and 16 weeks before treatment initiation Exclusion Criteria: - Multi-organ or re-transplant recipient - Evidence of current hepatitis B infection - Seropositive for human immunodeficiency (HIV) infection", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00087633.xml"}